Profiel
Victor S.
Sloan, MD joined Protalex, Inc. as Senior Vice President and Chief Medical Officer in August 2005.
Prior to joining Protalex, Dr. Sloan spent seven and a half years at Novartis Pharmaceuticals, most recently as Disease Area Section Head, Arthritis.
In this role he provided strategic direction for development and life cycle management of arthritis compounds.
Before joining Narvartis, Dr. Sloan was Assistant Professor of Clinical Medicine at Robert Wood Johnson Medical School in New Brunswick, NJ.
Dr. Sloan completed a Research Residency in Internal Medicine at Montefiore Medical Center, Bronx NY and Rheumatology subspecialty training at the University of California, San Francisco and the University of Medicine and Dentistry of New Jersey.
He is a graduate of New York Medical College in Valhalla, NY.
Dr. Sloan spent 2 years as a Visiting Scientist at Merck & Co. in Rahway, NJ.
Dr. Sloan holds appointment as Clinical Associate Professor of Medicine at Robert Wood Johnson Medical School, where he continues to see patients in a weekly rheumatology teaching clinic on a voluntary basis.
Dr. Sloan is a Fellow of the American College of Rheumatology and of the American College of Physicians.
He is a member of the Board of Directors of the Lupus Foundation of America, New Jersey Chapter and the Arthritis Foundation, New Jersey Chapter.
Eerdere bekende functies van Victor S. Sloan
Bedrijven | Functie | Einde |
---|---|---|
PROTALEX, INC. | Hoofd Techniek/Wetenschap/O&O | 02-01-2007 |
Opleiding van Victor S. Sloan
New York Medical College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Protalex, Inc.
Protalex, Inc. Pharmaceuticals: MajorHealth Technology Protalex, Inc. engages in the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases including rheumatoid arthritis and Immune Thrombocytopenia. Its lead product is PRTX-100 which is a bacterial protein known to modify aspects of the human immune system. The company was founded by John E. Doherty on September 17, 1999 and is headquartered in Florham Park, NJ. | Health Technology |